Characterisation of Toxicity Profiles of Immune and Molecularly Targeted Agents in Phase I and II Studies
Overall, more adverse events were reported with targeted therapies than with immunotherapy.
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
The Risk of irAEs After Immune Checkpoint Inhibitor Therapy May Not Be Elevated in Patients with Autoimmune Disease
Many cancer patients with autoimmune disease are excluded from studies of immune checkpoint inhibitors due to hypothesis of the association of this treatment with immune-related adverse events
EMA Recommends Granting a Conditional Marketing Authorisation for Dostarlimab
It is intended for the treatment of recurrent or advanced dMMR/MSI-H endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen
Increase in Node-Positive and Stage III Breast Cancer After Two Months Screening Interruption Due to COVID-19 Pandemic
A need for immediate restoration of breast cancer screening at full capacity
Final Results of the Collaborative EORTC/Intergroup Randomised Phase III Study of Adjuvant Imatinib in Localised GIST
After 9.1 years of follow-up, a trend toward better long-term imatinib failure-free survival in imatinib treated patients was observed in high-risk subgroup
FDA Approves Cemiplimab-rwlc for Advanced Non-Small Cell Lung Cancer With High PD-L1 Expression
Approval concerns the treatment of patients with tumours without EGFR, ALK or ROS1 aberrations
Five-Year Outcomes with CAR T Cell Therapy
Tisagenlecleucel outcomes in relapsed or refractory DLBCL and follicular lymphoma
EMA Pharmacovigilance Risk Assessment Committee Advice on Safety-Related Aspects of the Gene Therapy
Long-term follow-up due to risk of cancer
Prostate Cancer Genomics in Racial Minority Groups
Real-world findings
Efficacy and Safety of Adjuvant Pertuzumab, Trastuzumab and Chemotherapy After 6 Years Median Follow-Up in the APHINITY Study
Cardiac safety is confirmed with longer follow-up after adjuvant dual anti-HER2 treatment for node-positive, HER2-positive early breast cancer
pCR Correlates with RFS and OS with Neoadjuvant Therapy in Stage III Melanoma
It should be considered as an early surrogate endpoint for clinical trials
EMA Grants a Marketing Authorisation for Two Biosimilar Medicines, Bevacizumab
They received a positive opinion for the treatment of carcinoma of the colon or rectum, breast cancer, NSCLC, RCC, epithelial ovarian cancer, and carcinoma of the cervix